Overview

Low Dose IL-2 for Ulcerative Colitis

Status:
Completed

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of Interleukin-2 in subjects with moderate-to-severe ulcerative colitis.

Phase:

Phase 1

Details

Lead Sponsor:

Scott Snapper

Treatments:

Aldesleukin
Interleukin-2